Case Studies

Learn how Syngene ensured 100% first-time-right technology transfer for manufacturing limited number of batches of a novel compound to treat infections, including getting NDA approval in less than two years.

Learn how Syngene screened 50,000 compounds using high throughput screening against two different transcription factors for accelerated drug discovery.

Learn how Syngene screened a library of 200,000 compounds using high throughput screening for a single protein target for accelerated drug discovery.

Learn how Syngene partnered with a biotech company to deliver pre-IND to IND Safety studies in just three months for a treatment therapy for gut-brain diseases.

Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.

Learn how Syngene developed an antiparasitic tablet for dogs containing multiple APIs (one of which is a very low dose) in just six months.

Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.

Learn how Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101, while ensuring high chiral purity of 98% during GMP manufacturing